Coert J. Zuurbier

7.7k total citations · 3 hit papers
122 papers, 5.5k citations indexed

About

Coert J. Zuurbier is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Coert J. Zuurbier has authored 122 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 44 papers in Pathology and Forensic Medicine and 40 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Coert J. Zuurbier's work include Cardiac Ischemia and Reperfusion (44 papers), Diabetes Treatment and Management (29 papers) and Pancreatic function and diabetes (23 papers). Coert J. Zuurbier is often cited by papers focused on Cardiac Ischemia and Reperfusion (44 papers), Diabetes Treatment and Management (29 papers) and Pancreatic function and diabetes (23 papers). Coert J. Zuurbier collaborates with scholars based in Netherlands, Germany and United States. Coert J. Zuurbier's co-authors include Markus W. Hollmann, Ruben Coronel, Nina C. Weber, Cees A. Schumacher, Antonius Baartscheer, Anneke Koeman, Jan W.T. Fiolet, Peter A. Huijing, Can İnce and Otto Eerbeek and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Coert J. Zuurbier

118 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

2016 499 citations Coert J. Zuurbier et al. profile →
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

2017 466 citations Laween Uthman, Anneke Koeman et al. profile →
Direct cardiac effects of SGLT2 inhibitors

2022 111 citations Markus W. Hollmann, Nina C. Weber et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Coert J. Zuurbier Netherlands	43	2.1k	1.9k	1.5k	1.4k	874	122	5.5k
Katsuo Kanmatsuse Japan	36	1.2k 0.6×	755 0.4×	2.6k 1.7×	1.0k 0.8×	692 0.8×	273	5.7k
Kensuke Noma Japan	37	1.9k 0.9×	857 0.5×	2.1k 1.3×	977 0.7×	365 0.4×	97	6.0k
Motoaki Sano Japan	54	4.7k 2.2×	1.1k 0.6×	3.1k 2.0×	2.6k 1.9×	501 0.6×	225	10.3k
Carl S. Apstein United States	51	2.5k 1.2×	1.3k 0.7×	5.8k 3.8×	1.5k 1.1×	1.5k 1.7×	152	9.2k
Nina C. Weber Netherlands	35	1.1k 0.5×	1.1k 0.6×	963 0.6×	985 0.7×	1.2k 1.4×	126	4.0k
Fabio A. Recchia United States	46	3.5k 1.7×	599 0.3×	3.6k 2.4×	1.2k 0.9×	839 1.0×	141	8.4k
Takayuki Miki Japan	39	1.6k 0.8×	582 0.3×	1.5k 1.0×	613 0.5×	1.8k 2.1×	121	4.4k
Zequan Yang United States	36	1.1k 0.5×	313 0.2×	1.6k 1.1×	893 0.7×	1.1k 1.3×	87	4.6k
Kaie Ojamaa United States	40	2.3k 1.1×	3.2k 1.7×	1.5k 1.0×	851 0.6×	354 0.4×	90	5.7k
Stephen G. Ball United Kingdom	48	2.7k 1.3×	1.1k 0.6×	3.7k 2.4×	1.5k 1.1×	230 0.3×	245	8.8k

Countries citing papers authored by Coert J. Zuurbier

Since Specialization

Citations

This map shows the geographic impact of Coert J. Zuurbier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coert J. Zuurbier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coert J. Zuurbier more than expected).

Fields of papers citing papers by Coert J. Zuurbier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Coert J. Zuurbier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coert J. Zuurbier. The network helps show where Coert J. Zuurbier may publish in the future.

Co-authorship network of co-authors of Coert J. Zuurbier

This figure shows the co-authorship network connecting the top 25 collaborators of Coert J. Zuurbier. A scholar is included among the top collaborators of Coert J. Zuurbier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coert J. Zuurbier. Coert J. Zuurbier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marino, Alice, et al.. (2026). Sodium- myo -inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. Cardiovascular Research. 122(5). 578–592.

Bakker, Diane, et al.. (2025). Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism. Biomedicine & Pharmacotherapy. 185. 117967–117967. 1 indexed citations

Li, Xiaoling, Yasmeen M. Butt, Marta Z. Pacia, et al.. (2025). Sodium glucose co-transporter 2 inhibitor empagliflozin prevents endothelial dysfunction induced by oscillatory shear stress. Biomedicine & Pharmacotherapy. 192. 118670–118670.

Mericskay, Mathias, Coert J. Zuurbier, Lisa C. Heather, et al.. (2025). Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets. Nature Reviews Cardiology. 22(10). 704–727. 6 indexed citations

Xiao, Yang, Qian Wang, Hong Zhang, et al.. (2024). Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside. Basic Research in Cardiology. 119(3). 403–418. 1 indexed citations

Wijnker, Paul J.M., Björn C. Knollmann, Arie O. Verkerk, et al.. (2024). Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors. Cardiovascular Research. 120(3). 301–317. 15 indexed citations

Li, Xiaoling, et al.. (2024). Empagliflozin prevents TNF-α induced endothelial dysfunction under flow -the potential involvement of calcium and sodium-hydrogen exchanger. European Journal of Pharmacology. 986. 177147–177147. 7 indexed citations

Ferdinandy, Péter, Ioanna Andreadou, Gary F. Baxter, et al.. (2022). Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning. Pharmacological Reviews. 75(1). 159–216. 81 indexed citations

Li, Xiaoling, Raphaela P. Kerindongo, Jeroen Hermanides, et al.. (2021). Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species. International Journal of Molecular Sciences. 22(11). 6044–6044. 53 indexed citations

10.

Zuurbier, Coert J., Luc Bertrand, Ioanna Andreadou, et al.. (2020). Cardiac metabolism as a driver and therapeutic target of myocardial infarction. Journal of Cellular and Molecular Medicine. 24(11). 5937–5954. 146 indexed citations

11.

Uthman, Laween, Jeroen Hermanides, Markus W. Hollmann, et al.. (2020). Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells. Cardiovascular Drugs and Therapy. 35(6). 1083–1094. 54 indexed citations

12.

Smit, Kirsten, Raphaela P. Kerindongo, Coert J. Zuurbier, et al.. (2018). Helium alters the cytoskeleton and decreases permeability in endothelial cells cultured in vitro through a pathway involving Caveolin-1. Scientific Reports. 8(1). 4768–4768. 14 indexed citations

13.

Uthman, Laween, et al.. (2018). Administration of SGLT2 inhibitor empagliflozin against TNF-α induced endothelial dysfunction in human venous and arterial endothelial cells. Journal of Molecular and Cellular Cardiology. 120. 25–25. 2 indexed citations

14.

Nederlof, Rianne, Anneke Koeman, Laween Uthman, et al.. (2017). Cyclophilin D ablation is associated with increased end-ischemic mitochondrial hexokinase activity. Scientific Reports. 7(1). 12749–12749. 12 indexed citations

15.

Jong, Willeke M. C., Hugo Ten Cate, André C. Linnenbank, et al.. (2016). Reduced acute myocardial ischemia–reperfusion injury in IL-6-deficient mice employing a closed-chest model. Inflammation Research. 65(6). 489–499. 56 indexed citations

16.

Zuurbier, Coert J., Anneke Koeman, Sander M. Houten, Markus W. Hollmann, & Wouter J. Florijn. (2014). Optimizing anesthetic regimen for surgery in mice through minimization of hemodynamic, metabolic, and inflammatory perturbations. Experimental Biology and Medicine. 239(6). 737–746. 44 indexed citations

17.

Kapucu, Ayşegül, et al.. (2013). Hexokinase cellular trafficking in ischemia–reperfusion and ischemic preconditioning is altered in type I diabetic heart. Molecular Biology Reports. 40(7). 4153–4160. 25 indexed citations

18.

Smeele, Kirsten M., Otto Eerbeek, Anneke Koeman, et al.. (2010). Partial hexokinase II knockout results in acute ischemia–reperfusion damage in skeletal muscle of male, but not female, mice. Pflügers Archiv - European Journal of Physiology. 459(5). 705–712. 8 indexed citations

19.

Heinen, André P., Ragnar Huhn, Kirsten M. Smeele, et al.. (2008). Helium-induced Preconditioning in Young and Old Rat Heart. Anesthesiology. 109(5). 830–836. 80 indexed citations

20.

Mik, Egbert G., Tanja Johannes, Coert J. Zuurbier, et al.. (2008). In Vivo Mitochondrial Oxygen Tension Measured by a Delayed Fluorescence Lifetime Technique. Biophysical Journal. 95(8). 3977–3990. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact